Advertisement
Screener

ELOXX PHARMACEUTICALS, INC. (ELOX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

0.0 / 5 stars · 0/4 Roast Me

ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 23.72K shares.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 0.00 shares, a 100.00% decline year-over-year.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 19.97K shares, a 269.67% increase year-over-year.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 23.49K shares, a 36.50% increase from fiscal 2020.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 17.21K shares, a 85.21% decline from fiscal 2019.
  • ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 116.33K shares, a 91.28% decline from fiscal 2018.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2026-06-300.00 shares
derived: S-1 6 month − S-1/A 3 month · filed 2026-09-11
2026-03-3123.72K shares
S-1/A · filed 2026-06-04
2025-12-3118.25K shares
S-1 · filed 2026-09-11
2022-12-310.00 shares
10-K · filed 2023-03-31
2021-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
23.49K shares
10-K · filed 2022-03-30
2021-09-3019.97K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
2020-12-311.17K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
17.21K shares
10-K · filed 2021-03-12
2020-09-305.40K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
41.04K shares
derived: sum of 4 quarters · filed 2020-11-06
2020-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
65.17K shares
derived: sum of 4 quarters · filed 2020-08-07
2020-03-3110.64K shares
10-Q · filed 2020-05-08
101.96K shares
derived: sum of 4 quarters · filed 2020-05-08
2019-12-3125.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06
116.33K shares
10-K · filed 2020-03-06
2019-09-3029.54K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
503.32K shares
derived: sum of 4 quarters · filed 2019-11-06
2019-06-3036.79K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
729.18K shares
derived: sum of 4 quarters · filed 2019-08-07
2019-03-3125.00K shares
10-Q · filed 2019-05-09
2018-12-31412.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14
1.33M shares
10-K · filed 2019-03-14
2018-09-30255.39K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
2017-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13
0.00 shares
10-K · filed 2017-10-13
2017-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-22
0.00 shares
derived: sum of 4 quarters · filed 2017-10-13
2016-12-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-10
0.00 shares
derived: sum of 4 quarters · filed 2017-10-13
2016-09-300.00 shares
10-Q · filed 2016-11-14
0.00 shares
derived: sum of 4 quarters · filed 2017-10-13
2016-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13
0.00 shares
10-K · filed 2017-10-13
2016-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-12
0.00 shares
derived: sum of 4 quarters · filed 2017-10-13
2015-12-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-16
0.00 shares
derived: sum of 4 quarters · filed 2017-10-13
2015-09-300.00 shares
10-Q · filed 2015-11-16
0.00 shares
derived: sum of 4 quarters · filed 2017-10-13
2015-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13
0.00 shares
10-K · filed 2017-10-13
2015-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-14
0.00 shares
derived: sum of 4 quarters · filed 2016-10-13
2014-12-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-17
0.00 shares
derived: sum of 4 quarters · filed 2016-10-13
2014-09-300.00 shares
10-Q · filed 2014-11-14
0.00 shares
derived: sum of 4 quarters · filed 2016-10-13
2014-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13
0.00 shares
10-K · filed 2016-10-13
2014-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-09
0.00 shares
derived: sum of 4 quarters · filed 2015-10-09
2013-12-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-14
0.00 shares
derived: sum of 4 quarters · filed 2015-10-09
2013-09-300.00 shares
10-Q · filed 2013-11-14
2013-06-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-09
0.00 shares
10-K · filed 2015-10-09
2013-03-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15
2012-06-300.00 shares
10-K · filed 2014-09-29
2011-06-300.00 shares
10-K · filed 2013-09-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
BioStem Technologies, Inc. (BSEM)United States$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
Vaxart, Inc. (VXRT)United States$0.080B3.84
Tevogen Inc. (TVGN)United States$0.049B